Abstract YO12
Case summary
Case report : Hepatic EBV-associated Smooth Muscle Tumor (EBV-SMT)
A 51-year-old Thai man with history of HIV infection and chronic HBV hepatitis was sent to Vajira Hospital to evaluate liver lesions. He once had had pulmonary tuberculosis that was properly treated. Two years ago, the liver masses had been first identified on ultrasonography obtained routinely for HCC surveillance. At that moment, he was asymptomatic. His blood counts and blood chemistries including serum AFP were all unremarkable.
The triple-phase CT scan demonstrated two peripheral arterial enhancing masses with progressively enhanced on porto-venous and delayed phases, measured 5.7x4.7 cm and 4.2x3.4cm at segment IVa and IVb, respectively. Another enhancing nodule at porto-venous phase with decreased enhancement at delayed phase was found at segment V. Hepatic hemangioma had been considered and he had been advised to be closely observed, until three months ago, the repeated CT scan showed increasing size of the liver lesion at segment IVa to 6.0x4.7x5.1 cm, the rests were still stable in size.
At Vajira Hospital, he looked healthy. Physical examination was unrevealing. His blood count is normal. His blood chemistries were remarkable for mild elevation of ALT (194 U/L) (normal level, 46-116 U/L). His latest CD4 count and HIV viral load collected on 27/2/60 were 244/mm3 and less than 40 copies/mL, respectively. He was taking TDF/FTC/EFV.
MRI of upper abdomen revealed three progressively heterogeneously enhancing liver masses at segment at segment IVa, IVb, and V. The largest one was about 7.0x4.5x5.2 cm. The masses were in proximity of the left and middle hepatic veins. Percutaneous biopsy under CT guidance was done. It reported atypical spindle cell proliferation. IHC staining were positive for SMA and EBER, but negative for CD31, CD34, ERG, FLI-1, HHV-8, and Desmin. Thereby, EBV-SMT was diagnosed.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract